ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0299

Sex Hormones and Risk of Sjögren’s Syndrome: Hypothesis Generating Findings Implicating Androgen and Estrogen Ratios

Sara McCoy1, Christie Bartels2, Scott Hetzel1 and Jeffrey VanWormer3, 1University of Wisconsin, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI, 3Marshfield Research Institute, Marshfield, WI

Meeting: ACR Convergence 2021

Keywords: sex hormones, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Sjӧgren’s syndrome (SS) is the most female predominant systemic autoimmune disease, with peak onset around perimenopause. Estrogen appears to protect against SS, but prior studies lack details on surgical interventions and timing or type of exogenous hormone exposure. The purpose of this study was to determine how specific endogenous and exogenous hormone exposures contribute to SS Risk.

Methods: We performed a retrospective case-control study of adult women, nested within a defined population of Marshfield Clinic Health System (MCHS) patients in north-central Wisconsin. SS cases included patients with one SS diagnosis by a rheumatology provider or two SS diagnoses > 4 weeks apart from a non-rheumatology provider. Those with overlapping autoimmune diseases were excluded. Three controls were included for each SS case and were matched on age. We calculated a composite estrogen score (CES) for each patient, with one point for: 1) body mass index (BMI) ≥30 kg/m2, 2) menopause ≥55 years, 3) hormone replacement therapy >90 days, and 4) hysterectomy, which was considered a marker of high estrogen because hysterectomy is most often performed for fibroids and post-surgical management often includes exogenous hormones. Risk ratios for SS were reported, adjusted for age, race/ethnicity, and health insurance.

Results: There were 546 SS cases and 1,637 age-matched controls. The distribution of CES was 0 (n= 698 (32%)), 1 (n= 918 (42%)), 2 (n= 449 (21%)), and >= 3 (n=118 (5%)) (Table 1). Age, race, and ethnicity were similar between CES groups but health insurance differed. CES was not significantly associated with SS in adjusted models (Table 2). As outlined in Figure 1, the top three individual hormone exposures that were independently associated with SS included hirsutism (RR 2.42 [95% CI 1.32-4.43]), ovarian cysts, (2.12 [1.48-3.04]) and exogenous hormone replacement therapy (1.84 [1.20-2.81]). High BMI (0.62 [0.50-0.77]) and aromatase inhibitor use (0.25 [0.07-0.83]) appeared to be protective against SS.

Conclusion: Higher CES did not result in greater SS risk in this study, but several novel individual SS risk factors were observed, most notably hirsutism and ovarian cysts, which are associated with high androgen and lower estrogen excess. In contrast, high BMI, which is associated with higher levels of peripherally produced estrogen and lower androgen, was associated with lower SS risk. Aromatase inhibitor or SERM use also appeared protective, potentially representing confounding by indication because higher levels of estrogen are associated with breast cancer. These data suggest that the influence of sex hormones on SS pathogenesis may be more complex than prior studies have indicated; SS risk is potentially dependent on androgen-to-estrogen ratios. Further prospective studies are needed to confirm these findings.

Figure 1. Risk ratios and 95% confidence intervals of individual sex hormone exposure variables controlled for age at index, Caucasian, Ethnicity, and insurance type. Abbreviations: PCOS=polycystic ovarian syndrome; BMI=body mass index; OC=oral contraceptive; HRT=hormone replacement therapy; SERM=selective estrogen receptor modulator.


Disclosures: S. McCoy, BMS, 2, Novartis, 1, Boehringer Ingelheim, 6; C. Bartels, Pfizer, Independent Grants for Learning and Change, 5; S. Hetzel, None; J. VanWormer, None.

To cite this abstract in AMA style:

McCoy S, Bartels C, Hetzel S, VanWormer J. Sex Hormones and Risk of Sjögren’s Syndrome: Hypothesis Generating Findings Implicating Androgen and Estrogen Ratios [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/sex-hormones-and-risk-of-sjogrens-syndrome-hypothesis-generating-findings-implicating-androgen-and-estrogen-ratios/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sex-hormones-and-risk-of-sjogrens-syndrome-hypothesis-generating-findings-implicating-androgen-and-estrogen-ratios/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences